Diagnosis and Management of Statin Intolerance-Reference-Cited by-同舟云学术

Diagnosis and Management of Statin Intolerance

Published:2019-03-01 Issue:3 Volume:26 Page:207-215
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Alonso Rodrigo¹,Cuevas Ada¹,Cafferata Alberto²

Affiliation:

1. Department of Nutrition, Clinica Las Condes

2. Cardiovacular Prevention Department. Sanatorio Finochietto

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry (medical),Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/26/3/26_RV17030/_pdf

Reference58 articles.

1. 1) Piepoli M, Hoes A, Agewall S, Albus C, Brotons C, Catapano A, Cooney MT, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Løchen ML, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Eur Heart J, 2016; 37: 2315-2381

2. 2) Scandinavian Simvastatin Survival Group. Randomised Trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). The Lancet, 1994; 344: 1383-1389

3. 3) Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, Limacher M, Kell S, Glasser SP, Grant J, Davis BR, Pfeffer MA, Braunwald E. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med, 1998; 129: 681-689

4. 4) Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet, 2004; 363: 757-767

5. 5) LaRosa J, Grundy S, Waters D, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. Intensive Lipid Lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005; 352: 1425-1435

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Explore the mechanism of Citri Reticulatae Pericarpium (Chenpi) in atherosclerosis Based on Network Pharmacology, Molecular Docking and Experimental Evidence;2024-07-01

2. Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid;Journal of Cardiology;2024-07

3. Breaking down statin myopathy: understanding the self-limited and autoimmune subtypes;Rheumatology;2024-06-03

4. A Systematic Review and Meta-Analysis on the Role of Bempedoic Acid in Cardiovascular Outcomes for Patients With Statin Intolerance;Cureus;2024-06-03

5. Myopathies induites par les statines : une entité rare ?;Revue du Rhumatisme;2024-06